300676 Stock Overview
Provides sequencing services and a portfolio of genetic tests for medical institutions, research institutions, and other public and private partners in China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
BGI Genomics Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥44.80 |
| 52 Week High | CN¥56.89 |
| 52 Week Low | CN¥33.00 |
| Beta | 0.76 |
| 11 Month Change | -2.97% |
| 3 Month Change | 29.52% |
| 1 Year Change | -14.09% |
| 33 Year Change | -49.89% |
| 5 Year Change | -24.44% |
| Change since IPO | -29.99% |
Recent News & Updates
Recent updates
Shareholder Returns
| 300676 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | -4.4% | -2.6% | -2.1% |
| 1Y | -14.1% | -20.9% | 2.8% |
Return vs Industry: 300676 exceeded the CN Biotechs industry which returned -20.9% over the past year.
Return vs Market: 300676 underperformed the CN Market which returned 2.8% over the past year.
Price Volatility
| 300676 volatility | |
|---|---|
| 300676 Average Weekly Movement | 10.0% |
| Biotechs Industry Average Movement | 9.0% |
| Market Average Movement | 8.4% |
| 10% most volatile stocks in CN Market | 12.7% |
| 10% least volatile stocks in CN Market | 5.7% |
Stable Share Price: 300676 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 300676's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 3,752 | Lijian Zhao | www.bgi.com |
BGI Genomics Co., Ltd. provides sequencing services and a portfolio of genetic tests for medical institutions, research institutions, and other public and private partners in China and internationally. The company offers DNA, RNA, and customized sequencing services; and non-invasive prenatal testing, reproductive health screening, newborn genetic screening, and clinical exome sequencing services, as well as clinical and research solutions for oncology. It also offers laboratory solutions for the detection and diagnosis of patients suspected with COVID-19; SARS-CoV-2 IgM and IgG antibody detection kit; and real-time fluorescent RT-PCR kit for detecting SARS-CoV-2.
BGI Genomics Co., Ltd. Fundamentals Summary
| 300676 fundamental statistics | |
|---|---|
| Market cap | CN¥17.08b |
| Earnings (TTM) | -CN¥101.62m |
| Revenue (TTM) | CN¥4.03b |
4.2x
P/S Ratio-168.1x
P/E RatioIs 300676 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300676 income statement (TTM) | |
|---|---|
| Revenue | CN¥4.03b |
| Cost of Revenue | CN¥2.12b |
| Gross Profit | CN¥1.91b |
| Other Expenses | CN¥2.01b |
| Earnings | -CN¥101.62m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.27 |
| Gross Margin | 47.30% |
| Net Profit Margin | -2.52% |
| Debt/Equity Ratio | 3.5% |
How did 300676 perform over the long term?
See historical performance and comparison